Research programme: amylin receptor agonists - Kemia

Drug Profile

Research programme: amylin receptor agonists - Kemia

Latest Information Update: 26 Feb 2008

Price : $50

At a glance

  • Originator Kemia
  • Class Small molecules
  • Mechanism of Action Islet amyloid polypeptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Diabetes mellitus; Obesity

Most Recent Events

  • 26 Feb 2008 Preclinical development is ongoing
  • 22 Jun 2005 Kémia's oral amylin agonists programme is available for partnering in diabetes (http://www.kemia.com)
  • 12 May 2005 Preclinical trials in Obesity in USA PO
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top